NCT06446531View on ClinicalTrials.gov

Prevention of Progression of Prediabetes, Obesity and CV Risk

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Pre-DiabetesWeight, BodyCardiovascular Diseases
Interventions
DRUG

Placebo

Oral tablet administered once daily

DRUG

Rybelsus Tablet

Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.

DRUG

Jardiance 25Mg Tablet

Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily

DRUG

Metformin

Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)

DRUG

Actos

Oral tablet dosed at 15mg once daily

Trial Locations (1)

78229

RECRUITING

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

Baptist Health Foundation of San Antonio

UNKNOWN

lead

The University of Texas Health Science Center at San Antonio

OTHER